GLGS Glycogenesys Inc. (MM)

GlycoGenesys, Inc. (Nasdaq: GLGS), a biotechnology company focused on carbohydrate-based drug development, today announced that Dr. Finbarr Cotter, Professor, Barts and The London Queen Mary's School of Medicine UK, is scheduled to give a talk at the 9th International Conference on Malignant Lymphoma. The talk, entitled "GCS-100 A Novel Galectin-3 Antagonist and Caspace-9 Activating Therapy For Indolent B-Cell Malignancies", will be given during Session 16, New Immunological Principles (Room C) at 8:30 a.m. CEST June 11, 2005. Management's Comments Bradley J Carver, the Company's CEO and President stated, "We look forward to Dr. Cotter's new research on GCS-100 being presented to this distinguished global audience of clinicians, cancer researchers, and members of the biotechnology and pharmaceutical industry." GlycoGenesys, Inc. GlycoGenesys, Inc. is a biotechnology company focused on carbohydrate-based drug development. The Company currently is conducting a Phase I dose escalation trial of GCS-100LE, a unique compound to treat cancer, in patients with solid tumors at Sharp Memorial Hospital, Clinical Oncology Research in San Diego, California and the Arizona Cancer Center at Tucson and at Scottsdale, Arizona. In addition, the Company is conducting a Phase I/II dose escalation trial of GCS-100LE in multiple myeloma at the Dana-Farber Cancer Institute in Boston, Massachusetts. Further clinical trials are planned for 2005. The Company's headquarters are located in Boston, Massachusetts with a laboratory in Cambridge, Massachusetts. Additional information is available on GlycoGenesys' web site: www.glycogenesys.com. Safe Harbor Statement Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, risks of product development (such as failure to demonstrate efficacy or safety), risk related to FDA and other regulatory procedures, market acceptance risks, the impact of competitive products and pricing, the results of current and future licensing, joint ventures and other collaborative relationships, the results of financing efforts, developments regarding intellectual property rights and litigation, and other risks identified in the Company's Securities and Exchange Commission filings. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.